Long-term treatment of venous thromboembolism with tinzaparin compared to vitamin K antagonists: A meta-analysis of 5 randomized trials in non-cancer and cancer patients

Thrombosis Research

Volumn 130, Issue 6, 2012, Pages 853-858

  Laporte, Silvy ^a,b   Bertoletti, Laurent ^a,b   Romera, Antonio ^c   Mismetti, Patrick ^a,b   Pérez De Llano, Luis A ^d   Meyer, Guy ^e  

^a Hospital of Saint Etienne   (France)

^b UNIVERSITÉ JEAN MONNET   (France)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d HOSPITAL XERAL CALDE   (Spain)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Cancer; Long term treatment; Low molecular weight heparin; Tinzaparin; Venous thromboembolism

Indexed keywords

ACENOCOUMAROL; ANTIVITAMIN K; HEMOGLOBIN; TINZAPARIN; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CANCER PATIENT; CHRONIC PATIENT; COMPARATIVE EFFECTIVENESS; DATA EXTRACTION; DEEP VEIN THROMBOSIS; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTENTION TO TREAT ANALYSIS; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; LUNG ANGIOGRAPHY; LUNG EMBOLISM; META ANALYSIS; MORTALITY; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LONG-TERM CARE; MALE; MIDDLE AGED; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VITAMIN K; YOUNG ADULT;

EID: 84870254420     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2012.08.290     Document Type: Article

References (36)

1. M.D. Silverstein, J.A. Heit, D.N. Mohr, T.M. Petterson, W.M. O'Fallon, and L.J. Melton 3rd Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study Arch Intern Med [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.] 158 1998 585 593
2. R.H. White The epidemiology of venous thromboembolism Circulation 107 23 Suppl. 1 2003 I4 I8
3. M. Houman Fekrazad, R.D. Lopes, G.J. Stashenko, J.H. Alexander, and D. Garcia Treatment of venous thromboembolism: guidelines translated for the clinician J Thromb Haemost 28 2009 270 275
4. S. Noble, and J. Pasi Epidemiology and pathophysiology of cancer-associated thrombosis Br J Cancer 102 Suppl. 1 2010 S2 S9
5. G. Agnelli, and C. Becattini Treatment of DVT: how long is enough and how do you predict recurrence J Thromb Haemost 25 2008 37 44
6. R.D. Hull, G.F. Pineo, R. Brant, J. Liang, R. Cook, S. Solymoss LITE trial Investigators Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome Am J Med 122 2009 762 769 [e3]
7. C. Kearon, E.A. Akl, A.J. Comerota, P. Prandoni, H. Bounameaux, and S.Z. Goldhaber Antithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2 Suppl. 2012 e419S e494S
8. P. Mismetti, J.M. Baud, F. Becker, F. Belmahdi, P. Blanchard, and J. Constans Agence française de sécurité sanitaire des produits de santé. Guidelines for good clinical practice: prevention and treatment of venous thromboembolism in medical patients J Mal Vasc 35 2010 127 136
9. B.A. Hutten, and M.H. Prins Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism Cochrane Database Syst Rev 1 2006 CD001367
10. S. Schulman, C. Kearon, A.K. Kakkar, P. Mismetti, S. Schellong, and H. Eriksson Dabigatran versus warfarin in the treatment of acute venous thromboembolism N Engl J Med 361 2009 2342 2352
11. P. Prandoni, A.W. Lensing, A. Piccioli, E. Bernardi, P. Simioni, and B. Girolami Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis Blood 100 2002 3484 3488
12. J. Harenberg, G. Huhle, L. Piazolo, L.U. Wang, and D.L. Heene Long-term anticoagulation of outpatients with adverse events to oral anticoagulants using low-molecular-weight heparin Semin Thromb Hemost 23 1997 167 172
13. A. Iorio, F. Guercini, and M. Pini Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants J Thromb Haemost 1 2003 1906 1913
14. F. Veiga, A. Escriba, M.P. Maluenda, M. López Rubio, I. Margalet, and A. Lezana Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial Thromb Haemost 84 4 2000 559 564
15. M.L. Louzada, H. Majeed, and P.S. Wells Efficacy of low-molecular-weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials Thromb Res 123 2009 837 844
16. E.A. Akl, N. Labedi, M. Barba, I. Terrenato, F. Sperati, and E.V. Sempos Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer Cochrane Database Syst Rev 6 2011 CD006650
17. E.A. Akl, M. Barba, S. Rohilla, I. Terrenato, F. Sperati, and P. Muti Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review J Exp Clin Cancer Res 27 2008 21
18. A.Y. Lee, M.N. Levine, R.I. Baker, C. Bowden, A.K. Kakkar, and M. Prins Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer N Engl J Med 349 2003 146 153
19. D. Farge, L. Bosquet, D. Kassab-Chahmi, P. Mismetti, I. Elalamy, and G. Meyer 2008 French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working group Crit Rev Oncol Hematol 73 2010 31 46
20. M. Mandala, A. Falanga, and F. Roila Management of venous thromboembolism in cancer patients: ESMO clinical recommendations Ann Oncol 19 Suppl. 2 2008 ii126 ii127
21. D.A. Garcia, T.P. Baglin, J.I. Weitz, and M.M. Samama Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2 Suppl. 2012 e24S e43S
22. V. Siguret, E. Pautas, M. Fevrier, C. Wipff, B. Durand-Gasselin, and M. Laurent Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days Thromb Haemost 84 2000 800 804
23. I. Mahe, M. Aghassarian, L. Drouet, C. Bal Dit-Sollier, K. Lacut, and J.J. Heilmann Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study Thromb Haemost 97 2007 581 586
24. V. Launay-Vacher, S. Oudard, N. Janus, J. Gligorov, X. Pourrat, and O. Rixe Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study Cancer 110 2007 1376 1384
25. J.P. Higgins, D.G. Altman, P.C. Gotzsche, P. Jüni, D. Moher, and A.D. Oxman The Cochrane Collaboration's tool for assessing risk of bias in randomised trials BMJ 343 2011 d5928
26. J. Deeks, D. Altman, and M. Bradburn Statistical methods for examining heterogeneity and combining results from several studies in metaanalysis 2001 BMJ Books London
27. M. Egger, G.D. Smith, and A.N. Phillips Meta-analysis: principles and procedures BMJ 315 1997 1533 1537
28. J.A. Sterne, D. Gavaghan, and M. Egger Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature J Clin Epidemiol 53 2000 1119 1129
29. EasyMA.net [cited March 5, 2007] Available from: http://www.spc.univ- lyon1.fr/easyma.net
30. M.E. Daskalopoulos, S.S. Daskalopoulou, E. Tzortzis, P. Sfiridis, A. Nikolaou, and D. Dimitroulis Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial Eur J Vasc Endovasc Surg 29 2005 638 650
31. R.D. Hull, G.F. Pineo, R.F. Brant, A.F. Mah, N. Burke, and R. Dear Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms Am J Med 120 2007 72 82
32. A. Romera, M.A. Cairols, R. Vila-Coll, X. Martí, E. Colomé, and A. Bonell A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis Eur J Vasc Endovasc Surg 37 2009 349 356
33. L.A. Perez-de-Llano, V. Leiro-Fernandez, R. Golpe, J.M. Núñez-Delgado, A. Palacios-Bartolomé, and L. Méndez-Marote Comparison of tinzaparin and acenocoumarol for the secondary prevention of venous thromboembolism: a multicentre, randomized study Blood Coagul Fibrinolysis 21 2010 744 749
34. P. Lopez-Beret, A. Orgaz, J. Fontcuberta, M. Doblas, A. Martinez, and G. Lozano Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis J Vasc Surg 33 2001 77 90
35. G. Meyer, Z. Marjanovic, J. Valcke, B. Lorcerie, Y. Gruel, and P. Solal-Celigny Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study Arch Intern Med 162 2002 1729 1735
36. S.R. Deitcher, C.M. Kessler, G. Merli, J.R. Rigas, R.M. Lyons, J. Fareed ONCENOX Investigators Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period Clin Appl Thromb Hemost 12 2006 389 396